Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)

被引：4
|
作者：
Stein, Alexander
Binder, Mascha
Goekkurt, Eray
Lorenzen, Sylvie
Riera-Knorrenschild, Jorge
Depenbusch, Reinhard
Ettrich, Thomas Jens
Doerfel, Steffen
Al-Batran, Salah-Eddin
Karthaus, Meinolf
Pelzer, Uwe
Simnica, Donjete
Waberer, Lisa
Hinke, Axel
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Haematol Stem Cell Transplantat & Pneu, Hamburg, Germany
[2] Univ Med Ctr Halle Saale, Dept Internal Med 4, Halle, Germany
[3] Hematol Oncol Practice Eppendorf, Hamburg, Germany
[4] Univ Canc Ctr Hamburg, Hamburg, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med Hematol Med Oncol 3, Munich, Germany
[6] Univ Klin Marburg, Marburg, Germany
[7] Onkodok GmbH, Dedicated Res Facil, Guetersloh, Germany
[8] Ulm Univ Hosp, Ulm, Germany
[9] Onkozentrum Dresden, Dresden, Germany
[10] UCT Univ Canc Ctr, Krankenhaus Nordwest, Inst Clin Res IKF, Frankfurt, Germany
[11] Klinikum Neuperlach, Munich, Germany
[12] Charite, Berlin, Germany
[13] Univ Halle, Halle, Germany
[14] IKF GmbH Krankenhaus Nordwest, Frankfurt, Germany
[15] CCRC Canc Clin Res Consulting, Dusseldorf, Germany
[16] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[17] HOPE Hamatol Onkol Praxis Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium
    Sharma, M.
    Wroblewski, K.
    Kozloff, M.
    Modi, S. S.
    Sleckman, B. G.
    Taber, D.
    Vokes, E. E.
    Stadler, W. M.
    Polite, B. N.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [32] Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC)
    Becerra, C.
    Salazar, R.
    Garcia-Carbonero, R.
    Thomas, A. L.
    Vazquez-Mazon, F.
    Cassidy, J.
    Maughan, T.
    Gallen, M.
    Iveson, T.
    Hixon, M.
    Gualberto, A.
    Yin, D.
    Bergsland, E. K.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Final results and OS of the randomized phase II VOLFI trial (AIO-KRK0109): mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).
    Geissler, Michael
    Riera-Knorrenschild, Jorge
    Martens, Uwe Marc
    Held, Swantje
    Greeve, Jobst
    Florschuetz, Axel
    Ettrich, Thomas Jens
    Kanzler, Stephan
    Tannapfel, Andrea
    Heinemann, Volker
    Reinacher-Schick, Anke C.
    Seufferlein, Thomas
    Wessendorf, Swen
    Modest, Dominik Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Final phase II trial results of Sorafenib plus Capecitabine (SorCape) in previously treated metastatic colorectal cancer
    George, Thomas J.
    Ivey, Alison Marguerite
    Daily, Karen Colleen
    Dang, Long H.
    Watson, Scott
    McEwan, Margaret A.
    Lu, Xiaomin
    Tan, Sanda
    Iqbal, Atif
    Duff, Jennifer Michelle
    Allegra, Carmen Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data
    Siena, S.
    Tabernero, J.
    Burkes, R. L.
    Cassidy, J.
    Cunningham, D.
    Barugel, M. E.
    Humblet, Y.
    McPhie, C.
    Shing, M.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205
    von Wichert, G.
    Hoehler, T.
    Schimanski, C. C.
    Moehler, M. H.
    Hofheinz, R.
    Kanzler, S.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hacker, U. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] A phase II trial of capecitabine plus irinotecan (XELIRI) in a biweekly schedule in patients with untreated metastatic colorectal cancer (MCRC)
    Garcia Alfonso, Pilar
    Perez-Manga, Gumersindo
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Munoz, V.
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 120
  • [38] LONG TERM RESULTS OF A MULTICENTRE PHASE II TRIAL ASSESSING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS ACCORDING TO KRAS STATUS
    Samalin, E.
    Francoise, D.
    Thezenas, S.
    Bibeau, F.
    Viret, F.
    Mineur, L.
    Assenat, E.
    Bleuse, J.
    Portales, F.
    Crapez, E.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 23 - 23
  • [39] Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, J. A.
    Stuart, K.
    Zhu, A.
    Fuchs, C.
    Bhargava, P.
    Earle, C.
    Blaszkowsky, L.
    Lawrence, C.
    Battu, S.
    Ryan, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [40] Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL
    Nilsson, Sven
    Stein, Alexander
    Rolfo, Christian
    Kranich, Anne L.
    Mann, Julia
    Papadimitriou, Konstantinos
    Theile, Susann
    Amberg, Stefanie
    Bokemeyer, Carsten
    CURRENT CANCER DRUG TARGETS, 2020, 20 (10) : 811 - 817
12345